Eugia Unit III FDA observations and production halt
FDA issued Form 483 with 9 observations at Eugia Unit III; manufacturing paused, expected $20M revenue impact in Q4. Risk of prolonged shutdown and market share loss.
high · management_commentary
Aurobindo Pharma Limited — Q3 FY24
Aurobindo Pharma reported Q3 FY24 revenue of INR 7,352 crore (+14.7% YoY) and EBITDA margin of 21.8%, driven by strong US formulation growth (+28.9% YoY) and injectable/specialt...
bullish
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Potential market share loss in injectable products
Analyst raised concern about losing market share in key products from Eugia Unit III; management acknowledged risk but expects to recover with existing stock and phased restart.
medium · analyst_questionPenicillin G plant pricing risk
Analyst questioned profitability if Pen G prices fall below $20/kg; management deferred response, indicating uncertainty.
medium · analyst_questionBiosimilar commercialization delays
Pneumococcal vaccine missed national tender timeline; management indicated no near-term market entry, highlighting execution risk in biosimilar launches.
low · data_observation